Side-by-Side Comparison · 2026

Efinopegdutide vs Survodutide

Efinopegdutide vs Survodutide — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?

Efinopegdutide
GLP-1 Agonist

Efinopegdutide (MK-6024, HM12525A) is a PEGylated dual GLP-1R/glucagon receptor agonist developed by Hanmi Pharmaceutical and licensed to Merck (MSD). The PEG conjugation extends half-life to enable once-weekly dosing....

Calculate Efinopegdutide dose →
Survodutide
GLP-1 Agonist

Survodutide (BI 456906) is a dual agonist of GLP-1 receptors (GLP-1R) and glucagon receptors (GCGR) developed by Boehringer Ingelheim in collaboration with Zealand Pharma. Unlike tirzepatide (GLP-1/GIP) and semaglutide (GLP-1 only), survodutide adds glucagon receptor agonism whic...

Calculate Survodutide dose →
Key Parameters
Parameter Efinopegdutide Survodutide
Category GLP-1 Agonist GLP-1 Agonist
Research Phase 2 Phase 3
Half-Life ~7-10 days ~7 days (weekly dosing)
Typical Dose 0.3-1.0 mg weekly 0.6-4.8 mg weekly
Frequency Weekly Weekly
Route Subcutaneous injection Subcutaneous injection
FDA Status Investigational Investigational (Phase 3)

Calculate doses for both

Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.

Calculate Efinopegdutide Calculate Survodutide
Frequently Asked Questions
What is the difference between Efinopegdutide and Survodutide?
Efinopegdutide: Efinopegdutide (MK-6024, HM12525A) is a PEGylated dual GLP-1R/glucagon receptor agonist developed by Hanmi Pharmaceutical and licensed to Merck (MSD). The PEG conjugation extends half-life to enable o... Survodutide: Survodutide (BI 456906) is a dual agonist of GLP-1 receptors (GLP-1R) and glucagon receptors (GCGR) developed by Boehringer Ingelheim in collaboration with Zealand Pharma. Unlike tirzepatide (GLP-1/GI...
Which has a longer half-life, Efinopegdutide or Survodutide?
Efinopegdutide half-life: ~7-10 days. Survodutide half-life: ~7 days (weekly dosing).
Can you stack Efinopegdutide and Survodutide?
Efinopegdutide and Survodutide are in the same category and used together in research protocols. Always consult relevant literature and follow appropriate guidelines.

For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.